Capella, M. P., Pang, S. A., Magalhaes, M. A., & Esfahani, K. (2024). A review of immunotherapy in non-small-cell lung cancer. Current Oncology, 31(6), 3495–3512.

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., Russano, M., Anesi, C., Giusti, R., Filetti, M., Marchetti, P., Botticelli, A., Gelibter, A., Occhipinti, M. A., Marconcini, R., Vitale, M. G., & Ascierto, P. A. (2020). Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. Journal for Immunotherapy of Cancer, 8(2), e001361.

De Giglio, A., Aprile, M., Di Federico, A., Sperandi, F., Melotti, B., Gelsomino, F., & Ardizzoni, A. (2022). Impact of baseline versus intercurrent steroids administration on upfront chemo-immunotherapy for advanced non-small cell lung cancer (NSCLC). International Journal of Molecular Sciences, 23(18), 10292.

Giles, A. J., Hutchinson, M. N. D., Sonnemann, H. M., Jung, J., Fecci, P. E., Ratnam, N. M., Zhang, W., Song, H., Bailey, R., Davis, D., Reid, C. M., Park, D. M., & Gilbert, M. R. (2018). Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy. Journal for Immunotherapy of Cancer, 6(1), 51.

Goodman, R. S., Johnson, D. B., & Balko, J. M. (2023). Corticosteroids and cancer immunotherapy. Clinical Cancer Research, 29(14), 2580–2587.

Hong, S., Lee, J. H., Heo, J. Y., Suh, K. J., Kim, S. H., Kim, Y. J., & Kim, J. H. (2024). Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of health insurance review and assessment data. Journal of Cancer Research and Clinical Oncology, 150(4), 186.

Huang, J., Xiong, L., Tang, S., Zhao, J., & Zuo, L. (2024). Balancing tumor immunotherapy and immune-related adverse events: unveiling the key regulators. International Journal of Molecular Sciences, 25(20), 10919.

Jin, C., Qi, J., Wang, Q., Pu, C., & Tan, M. (2023). Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: A systematic review and network meta-analysis of randomized controlled trials. Frontiers in Oncology, 13, 1158690.

Jove, M., Vilariño, N., & Nadal, E. (2019). Impact of baseline steroids on efficacy of programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in patients with advanced non-small cell lung cancer. Translational Lung Cancer Research, 8(S4), S364–S368.

Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022). Impact of glucocorticoid use in oncology in the immunotherapy era. Cells, 11(5), 770.

Lea, S., Higham, A., Beech, A., & Singh, D. (2023). How inhaled corticosteroids target inflammation in COPD. European Respiratory Review, 32(170), 230084.

Li, M., Spakowicz, D., Zhao, S., Patel, S. H., Johns, A., Grogan, M., Miah, A., Husain, M., He, K., Bertino, E. M., Shields, P. G., Wei, L., Carbone, D. P., Otterson, G. A., Presley, C. J., & Owen, D. H. (2020). Brief report: Inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer. Cancer Immunology, Immunotherapy: CII, 69(11), 2403–2408.

Li, N., Zheng, X., Gan, J., Zhuo, T., Li, X., Yang, C., Wu, Y., & Qin, S. (2023). Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Chinese Medical Journal, 136(21), 2562–2572.

Mark, N. M., Kargl, J., Busch, S. E., Yang, G. H. Y., Metz, H. E., Zhang, H., Hubbard, J. J., Pipavath, S. N. J., Madtes, D. K., & Houghton, A. M. (2018). Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. American Journal of Respiratory and Critical Care Medicine, 197(3), 325–336.

Pitre, T., Kiflen, M., Ho, T., Seijo, L. M., Zeraatkar, D., & de Torres, J. P. (2022). Inhaled corticosteroids, COPD, and the incidence of lung cancer: A systematic review and dose response meta-analysis. BMC Pulmonary Medicine, 22(1), 275.

Qi, C., Sun, S. W., & Xiong, X. Z. (2022). From COPD to lung cancer: Mechanisms linking, diagnosis, treatment, and prognosis. International Journal of Chronic Obstructive Pulmonary Disease, 17, 2603–2621.

Ricciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019). Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. Journal of Clinical Oncology, 37(22), 1927–1934.

Scott, S. C., & Pennell, N. A. (2018). Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. Journal of Thoracic Oncology, 13(11), 1771–1775.

Shin, S. H., Park, H. Y., Im, Y., Jung, H. A., Sun, J. M., Ahn, J. S., Ahn, M. J., Park, K., Lee, H. Y., & Lee, S. H. (2019). Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. International Journal of Cancer, 145(9), 2433–2439.

Skribek, M., Rounis, K., Afshar, S., Grundberg, O., Friesland, S., Tsakonas, G., Ekman, S., & De Petris, L. (2021). Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. European Journal of Cancer, 145, 245–254.

Tareke, A. A., Debebe, W., Alem, A., Bayileyegn, N. S., Zerfu, T. A., & Ayana, A. M. (2022). Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease patients: A systematic review and meta-analysis. Pulmonary Medicine, 2022, 9799858.

Vynnychenko, O. І., Moskalenko, Y. V., Piddubnyi, A. M., & Moskalenko, R. A. (2025). Distribution of M1 and M2 macrophages and their impact on survival in non-small cell lung cancer. Reports of Morphology, 31(1), 37–44.

Weinmann, S. C., & Pisetsky, D. S. (2019). Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology, 58(S7), vii59–vii67.

Zeng, Z., Qu, J., Yao, Y., Xu, F., Lu, S., Zhang, P., Yao, Y., Li, N., Zhou, J., & Wang, Y. (2022). Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 22(1), 458.

Zhang, K., Zhou, C., Gao, J., Yu, P., Lin, X., Xie, X., Liu, M., Zhang, J., Xie, Z., Cui, F., Li, S., Passiglia, F., Stella, G. M., & Qin, Y. (2022). Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: A retrospective cohort study. Translational Lung Cancer Research, 11(11), 2306–2317.

Zhou, J., Chao, Y., Yao, D., Ding, N., Li, J., Gao, L., Zhang, Y., Xu, X., Zhou, J., Halmos, B., Tsoukalas, N., Kataoka, Y., de Mello, R. A., Song, Y., & Hu, J. (2021). Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Translational Lung Cancer Research, 10(5), 2148–2162.